Machine Learning In Clinical Trials: What Will The Future Hold (And What’s...
Machine learning is the subset of AI that is related to the development of algorithms that can make accurate predictions of future outcomes via pattern recognition and rules-based logic. Such use of...
View Article4 Ways Precision Medicine Impacts Cancer Treatment
Precision medicine is a potential game-changer and oncology expert Jeremy Schafer offers four ways that he believes precision medicine will change cancer treatment. Read the full article here. The post...
View ArticleTEDs’ Driving Change in U.S. Health Care
A focus on value-based care and other market drivers have led to the development of trendsetters, entrants and disruptors (TEDs). Precision for Value’s Dr. Oyekan and Jorge Font, discuss the five main...
View ArticleStandard of Care And The Internet Of Medical Things
Perhaps we should take a closer look at how Apple devices and other internet of things (IoT) technologies are impacting the healthcare landscape and have the potential to impact the standard of care...
View ArticleThe Evolution of Value Frameworks and What Is Next
Can the tools we use to measure value keep up with the pace at which oncology is advancing? Explore how four different frameworks have evolved over time and the role they play in oncology value...
View ArticleClik here to view.
New Issue of ALL ACCESS Available Now: The Key Takeaways of 2019
What are the biggest key takeaways from 2019? In the latest All Access newsletter by Precision for Value we asked our advisors to reflect on the market events for the year by type of payer. Get your...
View ArticleInnovative New Therapies, Uptick in M&A Activity Were Some 2019 Pharma...
The pharmaceutical industry remained in the headlines last year, although not always for the best reasons. Precision’s Andrew Cournoyer, RPh, and Dan Danielson, RPh, MS, give us their takes on the...
View ArticleWhy the dance between manufacturers and PBMs continues
There’s a simple reason why co-pay accumulators captured the industry’s attention when they rolled out in 2017: Healthcare is too damn expensive and co-pay accelerators, at least in theory, offered a...
View ArticlePharma Manufacturers Could See Better Adherence, Outcomes With Focus on SDOH
How much of a roll can pharmaceutical manufacturers play in the social determinants of health? Industry experts, Maureen Hennessey, PhD, and Dominic Galante, MD, discuss how much they can stand to gain...
View ArticleNew Orphan Drug Playing Field Requires Change in Tactics for Pharma Companies
Orphan drugs make up a growing slice of the pharmaceutical pipeline, with a significant share of new drug approvals, and payers are taking notice of their increasing market numbers and ultra-expensive...
View Article
